Anwar Roshanali Padhani MD, Presenter: Advisory Board, Acuitas Medical Ltd Advisory Board, Siemens AG Speakers Bureau, Siemens AG Researcher, Siemens AG Speakers Bureau, Johnson & Johnson

1) To show that DCE-MRI can be analyzed using qualitative to quantitative methods. 2) To illustrate that routine clinical use of DCE-MRI makes use of qualitative assessments. 3) To indicate that early drug development requires quantification including reproducibility assessments. 4) To realize that complex DCE analysis has roles in validation, drug development, and is needed for multiparametric assessments.

Using DCE-MRI in oncologic clinical practice should not be delayed/hindered by the complexities of the technique. The last 20 years of validation work allows us to be confident that DCE-MRI (morphology, subtraction maps, curve shapes & semi-quantitative methods) work in the clinic. Complex quantitative DCE analysis has roles in validation, drug development, and is needed for multiparametric assessments. Future work should now focus on incorporating mpMRI imaging for directing personalized medicine.

Padhani, A, Oncologic Applications of Quantitative DCE-MRI.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/12020941.html